

# Interoperability Standards May Silence EHR Babel

BY JOEL B. FINKELSTEIN  
Contributing Writer

WASHINGTON — Eliminating “the stupid clipboard” may be the simplest, most straightforward benefit that would come from electronic interoperability standards designed to allow physicians’ offices to communicate with hospitals, labs, insurers, and each other, according to Dr. John Halamka, the chairman of the Health Information Technology Standards Panel.

**As reimbursement and quality are linked, electronic records will be indispensable for documenting measures expected by payers.**

HITSP just delivered its first set of harmonization standards to the federal Office of the National Coordinator for Health Information Technology. The panel was convened just over a year ago by the American National Standards Institute (ANSI) under a Health and Human Services department contract to assist in the development of a Nationwide Health Information Network (NHIN).

The panel is developing a series of interoperability specifications that offer a road map for every vendor, hospital, and other stakeholder who wants to implement electronic health records that conform to a nationally recognized standard, Dr. Halamka said at a health care congress sponsored by the Wall Street Journal and CNBC.

For this first set, the panel sifted through 700 standards, a veritable hexadecimal soup including X12, HL7, NCPDP, and the Continuity of Care record, whittling that

down to 30. It was an emotional process that incorporated the best of all of those standards in what the panel calls a Continuity of Care Document, he said.

This is a work in progress, Dr. Halamka added. “As the industry begins to test these interoperability specifications we know there are going to be refinements. There are going to be areas of ambiguity that we need to clarify.”

“What’s going on at the [American Health Information] Community, at HIT-

SP, at the Certification Commission [for Healthcare Information Technology] are essential ingredients to successful transformation of health care,” said Dr. Michael Barr, vice president of practice advocacy and improvement at the American College of Physicians.

Unlike hospitals, small medical practices lack the resources to adopt electronic health records or other information technology, he said.

“There are knowledge barriers, there

are cost barriers,” said Dr. Barr, adding that it is difficult to figure all this out while running a practice.

But health information technology does pay for itself, and as reimbursement becomes increasingly linked to quality, electronic records will be indispensable for documenting measures expected by payers, he said.

Physician groups that have adopted EHR systems expect them to make it easier to adapt to new payment require-



One profile was created



The other was earned

## INDEX OF ADVERTISERS

<b>Bayer HealthCare LLC</b>	
Aspirin	13
<b>Boehringer Ingelheim Pharmaceuticals, Inc.</b>	
Flomax	38a-38b
<b>Forest Pharmaceuticals, Inc.</b>	
Lexapro	6a-6b
Namenda	26a-26b
<b>Eli Lilly and Company</b>	
Cymbalta	43-44
<b>Merck &amp; Co., Inc.</b>	
Zostavax	10a-10d
<b>Novartis Pharmaceuticals Corporation</b>	
Diovan HCT	9-10
<b>Novo Nordisk Inc.</b>	
NovoLog Mix 70/30	5-6
Levemir	31-32
<b>Pfizer Inc.</b>	
Viagra	3
Exubera	15-18
Caduet	22-25
Chantix	28-30
<b>Sanofi Aventis U.S. LLC</b>	
Lantus	40-42
<b>Sepracor, Inc.</b>	
Lunesta	18a-18b
<b>Takeda Pharmaceuticals North America, Inc.</b>	
Rozerem	36-38
<b>Wyeth Pharmaceuticals Inc.</b>	
Effexor XR	34a-34d

ments in the long run, but they offer the near-term benefits as well, said Bruce Metz, Ph.D., chief information officer for Thomas Jefferson University in Philadelphia.

The University's 500-physician group practice has spent the past 3 years implementing an \$18 million electronic records system with an expected 16%-30% return on investment. Insurance companies are not yet ready to pay the group a premium for the efficiencies the system brings, but because of improved documentation, the system has already allowed significant up-coding, he said.

Although more physicians are becoming

convinced of the benefits of EHR adoption, the government may be moving forward too aggressively, Dr. Barr said.

Congress wants Medicare to implement pay for performance now, although the industry is still struggling to identify appropriate measures. "The policy is well ahead of the practicality," he said.

If the experience with HIPAA Administrative Simplification proved anything, it was that having standards is only the beginning of the process, Dr. Halamka said. The next step is to work out a logical time frame for compliance, what are the incremental phases along the way and how to test compliance. ■

## UPCOMING MEETINGS

Anxiety Disorders Association of America  
National Kidney Foundation, Clinical Nephrology Meetings  
American Association of Clinical Endocrinologists  
International Conference on Community Acquired Pneumonia  
American Association for Cancer Research  
American College of Physicians  
Society of General Internal Medicine

We Are There For You


# Lantus®: the #1-prescribed insulin for good reason

## The #1 priority for people with diabetes-related hyperglycemia is to reduce blood glucose and A1C.<sup>1</sup>

Over the past 5 years, physicians like you have turned to Lantus® in steadily increasing numbers to do just that.\* Why? Because 5 years ago when you were wishing for a basal insulin that mimicked the way physiologic basal insulin works, Lantus® came along. It was then, and is still, the only once-daily, 24-hour basal insulin with no pronounced peak.<sup>2</sup> The result? Millions of prescriptions have been written for Lantus®.\* Lantus®, along with diet, exercise, and prandial and/or oral agents, allows patients to benefit from a full 24 hours of glucose lowering. Studies have shown Lantus® is associated with a low rate of hypoglycemia and has a neutral effect on weight.<sup>2-4</sup>

## Lantus® closely mimics physiologic basal insulin secretion.<sup>5,6</sup>

Physiologic basal insulin is secreted continuously over 24 hours, at a rate of approximately 0.5 IU/h, to meet between-meal and overnight glucose-regulating requirements and to suppress excess hepatic glucose production.<sup>6</sup> Past attempts at creating an insulin to mimic this profile have resulted in agents that have wide variability in their absorption and length of effect. Lantus® demonstrates a low rate of variability in its action, with a relatively flat, predictable profile after only 1 injection that lasts for a full 24 hours.<sup>2,7,8</sup> Additionally, in a crossover study of healthy volunteers, no differences in absorption rates were observed whether Lantus® was injected into the leg, arm, or abdomen.<sup>2,9</sup>



**Physiologic basal profile means patients are better able to plan when to eat**—because they don't have to contend with insulin peaks.<sup>6</sup> That can help patients by not requiring them to eat or snack at a specific time to balance a peak. In fact, Lantus® is associated with a low rate of hypoglycemia. It also has a neutral effect on weight.

## Lantus®, a basal insulin for patients with diabetes, has the features you want. It's what you've told us.

It's what you've *shown* us by making Lantus® the #1-prescribed insulin.

**Lantus® is the only once-daily, 24-hour basal insulin with no pronounced peak, and it closely mimics physiologic basal insulin secretion.<sup>2</sup>**

**It's tried. It's trusted.** And it's there for you as you help

more and more patients with diabetes toward control of blood glucose.

**We thank you for letting Lantus® help.**

Once-Daily  
24-HOUR  
**LANTUS®**  
insulin glargine [rDNA origin] injection

## Important Safety Information

Lantus® is indicated for once-daily subcutaneous administration, at the same time each day, for the treatment of adult and pediatric patients (6 years and older) with type 1 diabetes mellitus or adult patients with type 2 diabetes mellitus who require basal (long-acting) insulin for the control of hyperglycemia.

**LANTUS® MUST NOT BE DILUTED OR MIXED WITH ANY OTHER INSULIN OR SOLUTION. If mixed or diluted, the solution may become cloudy, and the onset of action/time to peak effect may be altered in an unpredictable manner.**

Lantus® is contraindicated in patients hypersensitive to insulin glargine or the excipients.

**Hypoglycemia is the most common adverse effect of insulin, including Lantus®. As with all insulins, the timing of hypoglycemia may differ among various insulin formulations. Glucose monitoring is recommended for all patients with diabetes. Any change of insulin type and/or regimen should be made cautiously and only under medical supervision. Concomitant oral antidiabetes treatment may need to be adjusted.**

Other adverse events commonly associated with Lantus® include the following: lipodystrophy, skin reactions (such as injection-site reaction, pruritus, rash), and allergic reactions.

**Please see brief summary of prescribing information on adjacent page.**

\*Based on PNRx. IMS Health. National Prescription Audit Plus™. September 2003 – December 2005.

**References:** 1. American Diabetes Association. *Diabetes Care*. 2005;28(suppl 1):S4-S36. 2. Lantus Prescribing Information. 3. Data on file, sanofi-aventis U.S. LLC (CSR HOE901/5001). 4. Data on file, sanofi-aventis U.S. LLC (CSR HOE901/5024). 5. Nathan DM. *N Engl J Med*. 2002;347:1342-1349. 6. Guthrie R. *Clin Diabetes*. 2001;19:66-70. 7. Scholtz HE, Pretorius SG, Wessels DH, Becker RHA. *Diabetologia*. 2005;48:1988-1995. 8. Fanelli CG, Pampanelli F, Porcellati P, et al. Poster presented at: 38th Annual Meeting of the European Association for the Study of Diabetes (EASD); September 1-5, 2002; Budapest, Hungary. 9. McKeage K, Goa KL. *Drugs*. 2001;61:1599-1624.